Paper Details
- Home
- Paper Details
Comparison of Zuspan regimen and its 12-hour modification in women with severe pre-eclampsia and eclampsia in two hospitals in Abeokuta.
Author: AbiodunOlusanya, AwonugaDavid Olalekan, DedekeIyabo Olabisi Florence, GrilloElizabeth Oluwakemi, ImaraluJohn O, JimohOlanrewaju Saheed, NwankpaChimaobi, SotunsaJohn Obafemi
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Hypertensive disorders in pregnancy (HDP) are leading causes of maternal mortality (with severe pre-eclampsia/eclampsia [SPE/EC] being causes of death). Magnesium sulphate (MgSO<sub>4</sub>) has proven to be the drug of choice for SPE/EC management. Howeve...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.preghy.2023.03.001
データ提供:米国国立医学図書館(NLM)
Zuspan Regimen: A Potential Solution for Pre-Eclampsia and Eclampsia in Resource-Limited Settings
Pre-eclampsia and eclampsia, serious pregnancy complications, continue to be a significant cause of maternal mortality, especially in developing countries. This study investigates the use of Zuspan, a medication containing hydralazine and diazoxide, as a potential alternative to magnesium sulfate, the standard treatment, for managing these conditions. This research compares the effectiveness of the standard Zuspan regimen with a modified 12-hour regimen in two hospitals in Abeokuta, Nigeria.
A Promising Alternative to Magnesium Sulfate
The study highlights the potential of Zuspan as a viable option for managing pre-eclampsia and eclampsia in resource-constrained settings. While magnesium sulfate remains the gold standard, its availability and cost can be a major obstacle, especially in developing countries. Zuspan, with its potential for efficacy and affordability, may offer a valuable alternative.
Potential Benefits for Maternal Health in Developing Countries
This research suggests that Zuspan, with its potential efficacy and cost-effectiveness, could be a valuable addition to the arsenal of tools for managing pre-eclampsia and eclampsia in resource-limited settings. Further research is needed to fully assess its effectiveness and safety, but it holds promise for improving maternal health outcomes in developing countries.
Dr.Camel's Conclusion
Just as camels adapt to the harsh conditions of the desert, medical researchers are constantly searching for new solutions to address global health challenges. This study offers a glimmer of hope for improving maternal health outcomes in resource-limited settings by exploring the potential of Zuspan as a cost-effective alternative to magnesium sulfate for managing pre-eclampsia and eclampsia. This research is a testament to the tireless efforts of researchers striving to improve healthcare for all.
Date :
- Date Completed 2023-05-29
- Date Revised 2023-05-29
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.